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Background: Recent studies emphasize the role of BRAF as a genetic marker for prediction, prognosis and risk
stratification in colorectal cancer. Earlier studies have reported the incidence of BRAF mutations in the range of
5-20% in colorectal carcinomas (CRC) and are predominantly seen in the serrated adenoma-carcinoma pathway
characterized by microsatellite instability (MSI-H) and hypermethylation of the MLH1 gene in the setting of the CpG
island methylator phenotype (CIMP). Due to the lack of data on the true incidence of BRAF mutations in Saudi
Arabia, we sought to analyze the incidence of BRAF mutations in this ethnic group.
Methods: 770 CRC cases were analyzed for BRAF and KRAS mutations by direct DNA sequencing.
Results: BRAF gene mutations were seen in 2.5% (19/757) CRC analyzed and BRAF V600E somatic mutation
constituted 90% (17/19) of all BRAF mutations. BRAF mutations were significantly associated with right sided tumors
(p = 0.0019), MSI-H status (p = 0.0144), CIMP (p = 0.0017) and a high proliferative index of Ki67 expression
(p = 0.0162). Incidence of KRAS mutations was 28.6% (216/755) and a mutual exclusivity was noted with BRAF
mutations (p = 0.0518; a trend was seen).
Conclusion: Our results highlight the low incidence of BRAF mutations and CIMP in CRC from Saudi Arabia. This
could be attributed to ethnic differences and warrant further investigation to elucidate the effect of other
environmental and genetic factors. These findings indirectly suggest the possibility of a higher incidence of familial
hereditary colorectal cancers especially Hereditary non polyposis colorectal cancer (HNPCC) syndrome /Lynch
Syndrome (LS) in Saudi Arabia.
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A complex network of genes are required for maintaining
the cellular homeostasis in colorectal tissue. In the original
multistep progression model of colorectal cancer (CRC)
first proposed by Vogelstein et al, normal colonic epithe-
lium gets transformed into benign (adenoma) neoplastic
epithelium followed by full blown invasive cancer and* Correspondence: kkuraya@kfshrc.edu.sa
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unless otherwise stated.eventually metastasis [1]. Over the years, significant ad-
vances in molecular genetics and caner biology have led
to the understanding that there exist 3 distinct molecular
phenotypes of CRC: (1) chromosomal instability(CIN) [2];
(2) microsatellite instability(MSI) [3]; and (3) the recently
discovered sessile and traditional serrated adenomas, a
subset of hyperplasic polyps that progress to serrated
carcinomas [4].
Some of the key signaling pathways implicated in colorec-
tal carcinogenesis are Epidermal Growth Factor Receptor
Signaling (EGFR) pathway, WNT signaling [1] and trans-
forming growth factor-β (TGF β) signaling [5]. Transla-
tional research has resulted in the bench-to-bedside
application of biomarkers like KRAS, BRAF and PI3K. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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nants of response to panitumumab and cetuximab therapy
in colorectal cancer is the presence of mutations in the
KRAS gene [7,8]. Testing for certain “activating” muta-
tions in the KRAS gene is currently one of the most widely
employed methods to predict responsiveness to EGFR in-
hibitors. Patients with presence of KRAS mutations in
their tumors do not respond to EGFR inhibitors. On the
other hand, a significant proportion of CRC patients with
the wild-type (normal) KRAS gene fail to respond to EGFR
inhibitors and mutations in other genes such as PIK3CA/
BRAF/NRAS/PTEN/TP53 have been implicated for resist-
ance in this subgroup of patients [7-9]. BRAF mutations
are known to be mutually exclusive with KRAS mutations
and Vaughn et al have reported that almost 8% of the
CRC subgroup with wild type KRAS gene had BRAF mu-
tations; these patients would receive EGFR inhibitors but
would be unresponsive to therapy [8].
Constitutive activation of the mitogen-activated pro-
tein kinase (MAPK) pathway regulates cellular prolifera-
tion, differentiation, and death. Oncogenic mutations in
the v-Raf murine sarcoma viral oncogene homolog B1
(BRAF) in CRC were first described by Davies et. al and
the commonest mutation was a single phosphomimetic
substitution in the kinase activation domain (V600E)
that led to activation of the MAPK pathway [10] Although
BRAF mutations have been identified in a variety of can-
cers, their highest incidence to the tune of almost 60% is
seen in melanomas [10]. The CRC subset that originates
from advanced serrated polyps have a distinct molecular
phenotype characterized by widespread hypermethylation
of CpG islands in the promoter regions of genes, referred
to as the CpG island methylator phenotype (CIMP) [11],
microsatellite instability (MSI) and oncogenic mutations in
BRAF gene [4,12,13]. Testing for BRAF mutation is benefi-
cial in judicious selection of patients for targeted therapy
[8,9] and also a cost effective approach in the HNPCC
(Hereditary Non-polyposis Colorectal Cancer) workup;
presence of BRAF mutation with absence of MLH1 pro-
tein is indicative of sporadic CRC [14,15].
In this study we comprehensively investigated the in-
cidence of BRAF mutations in Saudi CRC and its clinico-
pathological correlation, its association with molecular
markers and overall survival.
Materials and methods
Patients’ selection and TMA construction
A total of 770 patients with CRC diagnosed between
1990 and 2011 were randomly selected from King Faisal
Specialist Hospital and Research Centre (KFSHRC), and
Security Forces Hospital (SFH), Riyadh. A colorectal tissue
microarray was constructed comprising of 770 CRC sam-
ples as described previously [16]. Clinical and histopatho-
logical data were available for all these patients. Patientswith colon cancer underwent surgical colonic resection
and those with rectal cancer underwent anterior resection
or abdominoperineal resection. All node-positive colon
cancers received 5-fluorouracil-based adjuvant chemo-
therapy. A vast majority of the rectal cancers received
radiotherapy alone or chemoradiotherapy prior to sur-
gery, followed by adjuvant chemotherapy after surgery.
Colorectal Unit, Department of Surgery (KFSHRC and
SFH), provided long-term follow-up data about the date
and cause of death for this cohort of patients. Follow-up
was calculated from the date of resection of the primary
tumor, and all surviving cases were censored for survival
analysis on 31st December 2011. Two pathologists (P.B., S.P.)
reviewed all tumors for grade and histological subtype.
The institutional review board of the King Faisal Specialist
Hospital and Research Centre approved the study.
DNA isolation
DNA was extracted from paraffin-embedded CRC tissues
using Gentra DNA isolation kit (Gentra, Minneapolis, MN,
USA) following the manufacturer’s recommendations as
described previously [17].
PCR and DNA sequencing for KRAS and BRAF gene
KRAS and BRAF mutation analysis was performed on 755
and 757 CRC samples respectively. Primer 3 software was
used to design the primers for Exon 15 of BRAF; Exon
1, 2 of KRAS (Table 1). The PCR sequencing protocol
was same as described earlier [17]. The samples were fi-
nally analyzed on an ABI PRISM 3100xl genetic analyzer
(Applied Biosystems, Foster City, CA).
Microsatellite markers and analyses
Allelic imbalances were measured by performing micro-
satellite analysis on all matched normal and tumor tissue
by PCR amplification. A reference panel of five pairs of
microsatellite primers, comprising two mononucleotide
microsatellites (BAT25, BAT26) and three dinucleotide
microsatellites (DS123, D5S346 and D17S250) were used
to determine tumor MSI status [3]. Multiplex PCR was
performed in a total volume of 25 μl using 50 ng of gen-
omic DNA, 2.5 μl 10 × Taq buffer, 1.5 μl MgCl2 (25 mM),
Table 2 Correlation of BRAF Mutation with clinico-
pathological parameters in colorectal carcinoma
Total Positive Negative P
valueN % N % N %
Total number of cases 757 19 2.5 738 97.5
Age
< 50 years 246 32.5 3 1.2 243 98.8 0.0938
> 50 years 511 67.5 16 3.1 495 97.9
Sex
Male 394 52.0 11 2.8 383 97.2 0.6044
Female 363 48.0 8 2.2 355 97.8
Tumour site*
Left colon 600 83.0 10 1.7 590 98.3 0.0019
Right colon 123 17.0 9 7.3 114 92.7
Histological type
Adenocarcinoma 673 88.9 18 2.7 655 97.3 0.3673
Mucinous Carcinoma 84 11.1 1 1.2 83 98.8
Tumour stage*
I 88 12.2 4 4.6 84 95.4 0.6853
II 255 35.3 7 2.7 248 97.3
III 289 40.0 6 2.1 283 97.9
IV 90 12.5 2 2.2 88 97.8
Differentiation
Well 74 9.8 2 2.7 72 97.3 0.8887
Moderate 590 77.9 14 2.4 576 97.6
Poor 93 12.3 3 3.2 90 96.8
MSI-Molecular*
MSI-H 81 11.1 6 7.4 75 92.6 0.0144
MSI-S/L 651 88.9 13 2.0 638 98.0
KRAS Mutation*
Positive 216 28.7 2 0.9 214 99.1 0.0518
Negative 537 71.3 17 3.2 520 96.8
CIMP*
High 24 5.1 4 16.7 20 83.3 0.0017
Low & middle 444 94.9 8 1.8 436 98.2
*Data were not available (NA) for some cases for tumor site (NA = 34), Stage
(NA = 35), MSI-Molecular (NA = 25), KRAS Mutation (NA = 4), and CIMP (NA = 289).
Siraj et al. Molecular Cancer 2014, 13:168 Page 3 of 9
http://www.molecular-cancer.com/content/13/1/16810 pmol of fluorescent-labeled primers, 0.05 μl dNTP
(10 mM) and 0.2 μl Taq polymerase (1 Uμl − 1; all reagents
were from Qiagen Inc., Valencia, CA, USA). PCR was per-
formed using an MJ Research PTC-200 thermocycler. The
samples in which the novel alleles were found at one, and
two or more of those five loci were assigned MSI-L and
MSI-H respectively, and whereas samples without novel
alleles at any one of those loci were assigned MSS.
Statistical analysis
The JMP 10.0 (SAS Institute Inc., Cary, NC) software
package was used for data analyses. Survival curves were
generated using Kaplan-Meier method, with significance
evaluated using the Mantel-Cox log-rank test. Risk ratio
was calculated using the Cox proportional hazard model
in both univariate and multivariate analyses. Values of p
< 0.05 were considered statistically significant.
Results
Clinico-pathologic data
The characteristics of the 770 CRC patients are described
earlier [18]. The median age at the time of surgery was
57 years (inter quartile range [IQR], 47.7 -68.0 years). The
5 year overall survival of our study population was 70.6%.
BRAF mutation and their clinico-pathological correlation
Seven hundred fifty seven colorectal cancer cases were an-
alyzed for BRAF mutations and the remaining 13 cases
were not interpretable due to insufficient amount of DNA
and other technical reasons. Of the 757 cases analyzed for
BRAF status, BRAF mutations were observed in nineteen
cases and the incidence of BRAF in Saudi colorectal can-
cer was 2.5%( 19/757) (Table 2). Surprisingly this is among
the lowest incidence of BRAFmutations reported in litera-
ture (Tables 3 and 4). Of these 19 CRC with BRAF muta-
tions, 17 were seen in the V600E type and the other 2
were seen in V594G and V601E (Table 3 and Figure 1).
To reconfirm these results and rule out the fact that we
were missing any BRAF mutations due to tumor hetero-
geneity issues, cancer tissue was re-punched from 2-3 dif-
ferent tumor areas and BRAF analysis was repeated on
400 of these 757 samples. Repeat Sanger sequencing did
not show any discordance with earlier results and failed to
reveal any new cases with BRAF mutation. As shown in
Table 2, CRC with BRAF mutations were significantly as-
sociated with right sided tumors (p = 0.0019), microsatel-
lite instable MSI-H status (p = 0.0144) and CIMP high
phenotype (p = 00017). Of the 19 cases with BRAF muta-
tion, MSI-H, MSI-L and MSS were 6 cases (31.6%), 5
cases (26.3%) and 8(42.1%) cases respectively. The degree
of Ki-67 staining as a measure of proliferative index was
significantly higher in the BRAF mutation positive CRC
group (88.89 ± 12.78) as compared to the BRAF mutation
negative group (80.60 ± 25.30, p = 0.0162; Students T test;Additional file 1: Figure S1). A statistical trend was noted
with presence of BRAF mutation and older age (age > 50;
p = 0.0938) and a mutual exclusivity was observed with
KRAS mutations (p = 0.0518; a statistical trend was noted).
BRAF mutations were not associated with gender, hist-
ology subtype, tumor differentiation and Stage.
All the pathology reports of colonic biopsies and resec-
tion specimens and slides were reviewed to ascertain the
presence of serrated adenomas in the 19 cases with BRAF
mutations. We confirmed the presence of a serrated aden-
oma in only 1 case; hyperplastic polyps in 3 cases; tubular
Table 3 Clinical information, pathologic diagnosis, BRAF and KRAS testing results
Case # AGE Gender Histology
Type
Site Grade Stage BRAF KRAS CIMP MSI-PCR Pre-existing
Adenoma
BRAF-1 60 Male AC Caecum 2 I V601E Codon 13 Low CIMP MSI-L Tubular adenoma
BRAF-2 47 Male AC Ascending colon 2 I V600E Codon 13 NA MSI-S Hyperplastic polyp
SERRATED ADENOMA
BRAF-3 71 Female AC Rt colon 1 III V600E WT NA MSI-H Unremarkablemucosa
BRAF-4 57 Female AC Rt colon 3 IV V600E WT Low CIMP MSI-S Unremarkablemucosa
BRAF-5 67 Male AC Recto sigmoid 2 II V600E WT Low CIMP MSI-S Unremarkablemucosa
BRAF-6 74 Female AC Rt colon 3 II V600E WT Low CIMP MSI-H Unremarkablemucosa
BRAF-7 66 Male AC Ascending colon 2 III V594G WT Low CIMP MSI-L Adenoma
BRAF-8 68 Male AC Rt colon 2 IV V600E WT Low CIMP MSI-S Unremarkablemucosa.
BRAF-9 61 Female AC Rt colon 1 I V600E WT High CIMP MSI-H Small hyperplasticpolyps
BRAF-10 46 Male AC Sigmoid 2 I V600E WT NA MSI-L Hyperplastic polyp
BRAF-11 34 Male AC Recto sigmoid 2 III V600E WT Low CIMP MSI-S Unremarkablemucosa
BRAF-12 71 Male AC Sigmoid 2 III V600E WT NA MSI-S Hyperplastic polyp
BRAF-13 59 Male AC Rectal 2 III V600E WT High CIMP MSI-S Tubular adenoma
BRAF-14 66 Female AC Rt colon 2 II V600E WT NA MSI-H Unremarkable mucosa
BRAF-15 66 Male AC Sigmoid colon 2 II V600E WT Low CIMP MSI-S No colonic mucosa seen
BRAF-16 73 Female AC Rt colon 3 II V600E WT High CIMP MSI-H Unremarkable mucosa
BRAF-17 72 Male AC Rt colon 2 II V600E WT High CIMP MSI-H Unremarkable mucosa
BRAF-18 74 Female AC Sigmoid colon 2 II V600E WT NA MSI-L Unremarkable mucosa
BRAF-19 55 Female MC Recto sigmoid 2 III V600E WT NA MSI-L Unremarkable mucosa
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markable colorectal mucosa.
KRAS mutation and their clinico-pathological correlation
In our series of 770 CRC samples 755 were analyzable
for KRAS mutations and the incidence of KRAS muta-
tions was 28.6% (216/755; Additional file 2: Table S1).
The remaining 15 samples of the 770 CRC could not be
analyzed due to insufficient DNA or technical reasons.
Most of KRAS-mutated cases showed a mutation at
codon 12.
(152 cases; 70.3%) and codon 13 (64 cases; 29.7%).
KRAS mutations were associated with right-sided CRC
(p = 0.0064).
Co-existence of KRAS and BRAF mutation
The clinico-pathological and molecular characteristics of
the two CRC cases with co-existence of KRAS and BRAF
mutations - “BRAF-1” and “BRAF-2” are summarized in
Table 3. Both the patients were males with age > 40 years
(47 years and 60 years); MSI-L/MSS type; histology sub-
type of adenocarcinomas with moderate differentiation;
and Stage I cancer. Both these cases had mutation in
codon 13 for KRAS gene and the BRAF gene showed
mutation at V600E and V601E for BRAF-1 and BRAF-2
specimen respectively.Microsatellite instability analysis
MSI analysis data was available in 741 of the 770 samples
and the incidence of microsatellite instable (MSI-H),
microsatellite low (MSI-L) and microsatellite stable (MSS)
was 11.2%( 83/741), 18.6% (138/741) and 70.2% ( 520/741)
respectively. The remaining 29 samples could not be ana-
lyzed due to insufficient DNA, lack of paired normal DNA
or technical reasons.
BRAF mutation, KRAS mutation, and overall survival
The prognostic significance of KRAS and BRAF mutation
was analyzed with the use of the Kaplan–Meier method.
Patients with KRAS mutation had poorer survival as
compared to CRC with wild type KRAS gene (p = 0.0078)
(Figure 2A). In the multivariate analysis using the Cox
proportional hazard model (Additional file 3: Table S2) for
multiple factors such as age, gender, AJCC stage, microsat-
ellite instability and tumor differentiation, the relative risk
was 1.75 for CRC with KRAS mutation(95% CI 1.26-2.42;
p = 0.0011) and 6.70 for advanced AJCC stage(95% CI
4.78-9.31; p ≤ 0.0001). Thus, KRAS mutation was an inde-
pendent prognostic marker for poor survival in CRC
across all stages. We also assessed the overall survival of
KRAS mutation at codon12 and codon13. Amongst the
KRAS-mutated cases, mutation in codon 12 was associ-
ated with the worst survival (62.8%; p = 0.0230) compared
Table 4 Summary of previous studies on BRAF mutation in colorectal carcinoma




Methods of mutation detection
Li-Ling H, 2012 Taiwan 1.1 2/182 High-resolution melting point (HRM) polymerase chain reaction
(PCR) for BRAF V600E mutations
Li H , 2011 China 7 14/200 Sequenced by Pyrosequencer PyroMark ID system-Exon 15, V600E
Liou J, 2011 China 3.8 12/314 Sequencing of exons 11 and 15
Yokota T, 2011 Japan 4.7 15/319 Cycleave PCR technique for V600E mutation
Nakanishi R, 2012 Japan 6.7 17/254 BRAF pyrokit pyrosequencing
Ajay Goel, 2009 Israel 18.7 24/128 Direct sequencing using the BigDye version 1.1 cycle-sequencing kit
Rozek L, 2010 Israel 5 65/1300 Direct sequencing of exon 15 of BRAF
Price T, 2011 Australia 10.6 33/315 High-resolution melting point (HRM) polymerase chain reaction
(PCR) for BRAF V600E mutations
Tran B, 2011 Australia 11 57/524 Mutation-specific real-time polymerase chain reaction assay.
Di Nicolantonio, 2008 Italy 10 11/113 Automated sequencing by ABI PRISM 3730 exon15
Richman S, 2009 UK 7.9 422/711 Pyrosequenced on a PyroMark ID system (Biotage AB) Codon 600
Roth A, 2009 Switzerland 7.9 103/1307 Allelic discrimination assay on a 7500 real-time polymerase chain
reaction for V600E
Zlobec I, 2010 Switzerland 12 45/374 BRAF (exon 15 codon 600) direct sequencing of single-stranded




Netherlands 19.8 59/297 V600E mutation on the BRAF gene by real-time PCRLight Cycler
v2.0 (Roche)
Saridaki Z, 2010 Greece 8.3 12/144 Real-time PCR using the allelic discrimination method with ABI
PRISM 7900 T Sequence Detection System
Modest D, 2012 Germany 11.6 17/146 Exons 11 and 15 of the BRAFpyro-sequencing
Samowitz W, 2005 USA 9.5 87/911 Sequencing in both directions
Shaukat A,2010 USA 21.8 36/165 BRAF V600E mutation -Mutector II BRAF/Ras mutation detection
panel assay kit
Kalady M,2012 USA 12 56/475 Direct sequencing
Ogino S,2012 USA 15 11/75 c.1799 T > A (p.V600E) mutation
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tations (73.5%). BRAF mutation was not associated with
any prognostic significance (p = 0.3310; Figure 2B).
Discussion
Accumulating evidence implicates BRAF mutations to
have diagnostic, therapeutic and prognostic significance
in CRC [10,19-22]. In our study, the BRAF-V600E muta-
tion was identified in only 2.5% of all CRC, which is sig-
nificantly lower than earlier reports of BRAF mutation
in CRC worldwide (5-15%; [22-26]). The overall low fre-
quency of the BRAF-V600E mutation and serrated aden-
omas in this unique ethnic group of Saudi colorectal
cancer cases suggests a very small role of the BRAF gene
in the development of CRC and raises some interesting
future questions on the burden of familial colorectal
cancers like Hereditary non polyposis colorectal cancer
cancer(HNPCC) syndrome in Saudi Arabia.
The reported frequency of BRAF mutations in differ-
ent populations varies widely from a low incidence of 1%in Taiwan to 19.8% and 21.8% in Netherlands and USA
respectively [22-25,27-40]. A lower frequency has been
observed in most of the Asian population as is evident
from the lowest BRAF mutation incidence of 1% in
Taiwan where BRAF mutation was seen in 2/182 CRC. A
similar low incidence was seen in China (3.8% and 7%)
and Japan (4.7% and 6.7%). BRAF mutation was also ob-
served at a lower rate of 5% in Israel [39]. Interestingly the
frequency of the BRAF V600E mutation varies widely be-
tween population groups, both within single studies (5.8%
in the Ashkenazi versus 3.2% in the non-Ashkenazi) and
also between reports from different groups but within the
same region/country [36,41]. The lower incidence of
BRAF mutations in Saudi CRC patients could be due to a
different ethnic populations with varied underlying genetic
predisposition to BRAF-mutated tumors, role of environ-
mental influences like diet, smoking and other unknown
factors. Different methods used to detect gene mutation
such as 454 next generation sequencing, Sanger sequencing,
pyrosequencing and melting curve analysis also influence
Figure 1 Example of BRAF gene mutations in CRC. Sequencing traces of cases harboring wild type (A), and V600E (B), D594G (C) and K601E
(D) mutations, respectively.
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study has highlighted the differing rates of BRAF mutation
in distinct ancestral populations with a lower frequency
observed in Asian population as compared to White and
Black patients in their study [43].
Although BRAF mutations occur early in colorectal
carcinogenesis and have been observed in colorectal ad-
enomas, tumor progression needs additional acquired
DNA microsatellite instability caused by hypermethylation
of MLH1 in the setting of the CpG island methylator
phenotype (CIMP) [12,44]. These precursor lesions thatFigure 2 Impact of KRAS and BRAF mutations in CRC and the Kaplan–
mutations had reduced overall survival of 63.5% at 5 years compared with
was no significance in survival between BRAF mutated and non mutated charbor BRAF mutation, microsatellite instability and CIMP
phenotype have a distinct morphology and are termed ser-
rated adenomas. A retrospective review of all the available
biopsies of hyperplastic polyps and adenomas biopsies
confirmed the presence of only one case that had a
morphology consistent with serrated adenomas. Add-
itional efforts to identify serrated adenomas from the
FFPE archives of Department of Pathology confirmed the
fact that serrated adenomas were exceedingly rare. We
have analyzed CIMP in 500 CRC patients and have observed
a very low frequency of CIMP of 4.8% (data not shown).Meier. Survival analysis. (A) Colorectal cancer patients with KRAS
73.5% without KRAS mutations (p = 0.0078). (B) In CRC patients, there
ases. (p = 0.3310).
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lack of a propensity for hypermethylation and other fac-
tors in Saudi CRC prevents the driver BRAF mutation in
premalignant lesions to progress to full blown cancers
[13]. Although smoking is one of the factors implicated in
CIMP phenotype and the incidence of smoking in Saudi
Arabia is quite high [45,46], the prevalence of BRAFmuta-
tions, CIMP and serrated adenomas in our study popula-
tion was on the lower side. Moreover, the significantly
lower incidence of BRAF mutations in our study suggests
the existence of a possibly higher number of familial syn-
dromes like HNPCC that are characterized by a virtual
lack of BRAF abnormalities in colorectal cancers. A study
is being conducted to determine the true incidence of
HNPCC in Saudi Arabia. Presence of BRAF V600E muta-
tion in CRC tumors that lacks the expression of MLH1 by
IHC does not warrant further genetic testing and excludes
the possibility of the presence of a germline mutation in
mismatch repair (MMR) genes. This exquisite sensitivity
of BRAF V600E somatic mutation for sporadic MSI has
led to the development of an algorithm for screening of
LS as a multistep diagnostic approach in several guidelines
and recommendations [15,47]. Since a significant propor-
tion of sporadic CRC get excluded, the use of BRAF
V600E as a screening tool to identify sporadic MSI CRC
tumors is highly cost effective [15,47,48]. Newer develop-
ments in the detection of BRAF V600E mutation in CRC
by IHC have shown to have a comparable sensitivity and
specificity as PCR testing [49]. After stringent validation
of BRAF IHC in each lab, BRAF testing by IHC will prove
to be a simple, economical, labor and time saving test that
can be performed even in small biopsies that yield a small
amount of DNA. Finally Weisenberger et al investigated
CIMP in CRC and demonstrated that MSI-H CRC are ei-
ther HNPCC or MSI-H and CIMP +with or without
MLH1 methylation [50]. The authors concluded that
CIMP + encompass almost all sporadic MSI-H CRC while
MLH1 methylation constitute a part of, but not all CIMP+
CRC tumors. Since BRAF mutations distinctly correlate
with CIMP + CRC, BRAF testing could outperform MLH1
methylation in identifying sporadic MSI-H CRC tumors in
the diagnostic approach of LS [50].
Emerging studies highlight the critical significance of
the impact of BRAF mutations on colorectal research.
Although there has been remarkable success in using
BRAF inhibitors in melanomas with a response rate of
over 80%, a lower response rate of about 10% is seen in
CRCs [20]. A key mechanism causing resistance to BRAF
inhibitors in CRC is upregulation of the EGFR pathway
and a combination therapy with EGFR inhibitors and
BRAF inhibitors might prove effective [20]. Dual syner-
gism could guide strategies that aim to improve outcomes
especially in patients who are refractory to initial lines
of therapy.In conclusion, we observed a very low incidence of CRC
with BRAF mutations that showed a significant associ-
ation with right sided tumors, CIMP high phenotype and
microsatellite instability. Future work would be directed
to establish an effective screening program to study the
prevalence of HNPCC cases in Saudi Arabia and also try
to understand the complex interaction between genetics
and environmental factors that contribute to this low inci-
dence of BRAF mutations in this region.
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